Discovery and Characterization of ALPL as A Potential Drug Target Or Biomarker

Target Name: ALPL

NCBI ID: G249

Discovery and Characterization of ALPL as A Potential Drug Target Or Biomarker

ALPL (alpha-lipoprotein lipase) is a protein that is expressed in various tissues throughout the body, including fat cells, muscle cells, and the liver. It is a lipase enzyme that is involved in the breakdown of fatty acids, which is essential for energy metabolism. The discovery and characterization of ALPL as a potential drug target or biomarker has significant implications for the treatment of various diseases, including obesity, non-alcoholic liver disease and diabetes.

ALPL is a 16kDa protein that is expressed in human tissues, including fat cells, muscle cells, and the liver. It is a lipase enzyme that is involved in the breakdown of fatty acids, which is essential for energy metabolism. The liver is a major organ that is responsible for breaking down fatty acids from the food we consume to provide energy to the body.ALPL is a key enzyme that is involved in this process and is expressed in high levels in the liver.

Recent studies have characterized ALPL as a potential drug target or biomarker for various diseases, including obesity, non-alcoholic fatty liver disease (NAFLD), and diabetes.

Obesity is a significant public health issue that is associated with various diseases, including cardiovascular disease, diabetes, and certain cancers. ALPL is a potential drug target for obesity because it is involved in the breakdown of fatty acids, which is a key component of fat .Obesity is characterized by an excess of body fat, which is associated with an increased risk of these diseases. Therefore, targeting ALPL to reduce fat mass and improve energy metabolism could be an effective way to treat obesity.

ALPL has also been studied as a potential biomarker for NAFLD.NAFLD is a condition that is characterized by the accumulation of fat in the liver, which can lead to the development of certain diseases, including liver cirrhosis and nonalcoholic steatohepatitis (NASH).ALPL is expressed in high levels in the liver and is involved in the breakdown of fatty acids, which is essential for the metabolism of fat. Therefore, measuring the level of ALPL in the liver could be a useful diagnostic tool for NAFLD and could help identify therapeutic potential approaches.

ALPL has also been studied as a potential drug target for diabetes. Diabetes is a disease that is characterized by the failure of the body to produce or use insulin, leading to high levels of glucose in the blood. ALPL is involved in the breakdown of fatty acids, which is essential for energy metabolism. Therefore, targeting ALPL to improve insulin sensitivity and glucose metabolism could be an effective way to treat diabetes.

In summary, ALPL is a protein that is involved in the breakdown of fatty acids and is expressed in various tissues throughout the body.The discovery and characterization of ALPL as a potential drug target or biomarker for obesity, NAFLD, and diabetes has significant implications for the treatment of these diseases. Further research is needed to fully understand the role of ALPL as a potential drug target or biomarker and to develop effective therapeutic approaches.

Protein Name: Alkaline Phosphatase, Biomineralization Associated

Functions: Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis (PubMed:12162492, PubMed:23688511, PubMed:25982064). Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural substrates (PubMed:12162492, PubMed:2220817). Plays an essential role in skeletal and dental mineralization via its ability to hydrolyze extracellular diphosphate, a potent mineralization inhibitor, to phosphate: it thereby promotes hydroxyapatite crystal formation and increases inorganic phosphate concentration (PubMed:23688511, PubMed:25982064). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity). Also promotes dephosphorylation of osteopontin (SSP1), an inhibitor of hydroxyapatite crystallization in its phosphorylated state; it is however unclear whether ALPL/TNAP mediates SSP1 dephosphorylation via a direct or indirect manner (By similarity). Catalyzes dephosphorylation of PLP to pyridoxal (PL), the transportable form of vitamin B6, in order to provide a sufficient amount of PLP in the brain, an essential cofactor for enzymes catalyzing the synthesis of diverse neurotransmitters (PubMed:2220817, PubMed:20049532). Additionally, also able to mediate ATP degradation in a stepwise manner to adenosine, thereby regulating the availability of ligands for purinergic receptors (By similarity). Also capable of dephosphorylating microbial products, such as lipopolysaccharides (LPS) as well as other phosphorylated small-molecules, such as poly-inosine:cytosine (poly I:C) (PubMed:28448526). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating hydrolysis of N-phosphocreatine to initiate a futile cycle of creatine dephosphorylation and phosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity)

More Common Targets